Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
Carregando...
Data
2012-07-24
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Biomed Central Ltd.
Tipo
Artigo
Direito de acesso
Acesso aberto
Resumo
Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4(+) and CD8(+) T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 mu g/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
Descrição
Palavras-chave
Idioma
Inglês
Como citar
Bmc Complementary and Alternative Medicine. London: Biomed Central Ltd., v. 12, p. 6, 2012.